Focal Irreversible Electroporation

Prostate Cancer Treatment With NanoKnife® IRE

Professor Phillip Stricker, St Vincent's Clinic, St Vincent's Prostate Cancer Centre, Garvan Institute, Kinghorn Cancer Centre.
Team: Alexander Blazevski MD, Brian Yuen MD, John Chang MD, Jayne Matthews, Angela Papazoglou, Anne-Marie Haynes, Matthijs Scheltema MD, Willemien Van Den Bos MD, , Amer Amin MD, Thomas Cusick, William Gondoputra MD

The NanoKnife® System has received FDA clearance and TGA clearance for the surgical ablation of soft tissue.

Why We Treat Some Prostate Cancers With Focal IRE

Whilst most prostate cancers occupy large areas of the prostate, there are some that occupy less than half and often less than a quarter of the prostate gland. These more focal prostate cancers probably constitute about 20% of all prostate cancers. With high quality 3T multiparametric MRI combined with template 3D transperineal biopsies and sometimes combined with PSMA PET scanning, it is now much more possible to identify this select group of patients. The advantage of focal treatments of the prostate with energy sources such as the NanoKnife allow eradication of the cancer with minimal side effects.

Whole-gland therapies such as surgery, radiotherapy and brachytherapy have a long and established track record in the treatment of multifocal and high grade prostate cancer. However, their use in more focal cancers may be regarded as overtreatment based on recent data from a large randomised trial ( PROTECT trial ). Furthermore, radical prostatectomy, radiotherapy and brachytherapy have a significant side effect profile including urinary incontinence, impotence and rectal damage which are largely avoided by focal NanoKnife therapy.

How is Focal IRE Done?

After a full workup to ensure that our patients are suitable for the program they then undergo a day surgery procedure which takes between 40 and 60 minutes. Depending on the extent of the cancer this may simply ablate the lesion, a quarter of the prostate or a half of the prostate. No prostate cancer cells are resistant to this treatment. Large areas can be treated with minimal side effects.

After the treatment patients stay in the day surgery unit for two to four hours and they are discharged home with a Foley catheter in place. Postoperatively pain is minimal and patients are discharged with tablets for mild pain, moderate pain, bladder spasms and relaxation of the prostate and antibiotics as required.

On day 2 a limited multiparametric MRI is performed. The Foley catheter is left in for two to five days depending on the extent of the treatment.

Who Is The Right Type Of Patient?

Inclusion Criteria:

  • Focal gleason large-volume Gleason 6 prostate cancer, Gleason 3+4=7 focal prostate cancer and Gleason 4+3=7 focal prostate cancer and select low-volume Gleason 4+4 prostate cancer.
  • PSA < 15
  • MRI identifiable tumour which correlates perfectly with targeted biopsies.
  • Template biopsies confirmed no significant prostate cancer outside of this region or outside of that side of the prostate.
  • Patient refuses standard therapies such as surgery, radiotherapy and brachytherapy.
  • Patient over 55 and preferably over 60.
  • Patient fit for general anaesthesia.
  • Patient accepts the need for ongoing monitoring.

Outcomes

<

All patients have been meticulously followed up (100% follow up) with high-quality MRIs and biopsies, in addition to being offered validated quality of life questionnaires.

Our current outcomes for focal irreversible electroporation in the primary setting (not after radiotherapy) is:

  • 97% clearance of the primary tumour.
  • 0% ongoing incontinence.
  • Less than 10% erectile dysfunction.
  • 20% chance of retrograde ejaculation
  • No major (Clavien 3 or 4) complications.
  • Less than 20% recurrence in other parts of the prostate (up to 12 year Follow up), one third of which had successful redo treatments.
  • Over 100 patients had focal IRE after prior radiation treatment with no major complications, < 1% major complication, < 10% incontinence and < 40% erectile dysfunction with 80% clearance of the primary tumour and 60% overall tumour control

Our Nanoknife publications can be found here.

Follow-up

Three-monthly PSAs.

Quality of life questionnaires are offered from our research team.

Multiparametric MRI at six months.

Transperineal biopsy at 12 months.

Possible PSMA PET scanning if these studies are indeterminate.

Ongoing Active Surveillence

Compared

Focal Ire Versus Robot-Assisted Nerve-Sparing Surgery

FOCAL IRE NERVE-SPARING ROBOT-ASSISTED SURGERY
Minimally invasive Keyhole surgery
Day surgery procedure. One to two days in hospital
Two to five day Foley catheter. Six day Foley catheter
Minimal recovery Three to six week recovery
Mild discomfort. Mild to moderate pain.
<1% Major Complications < 1% major complications.
0% incontinence 1-2% ongoing incontinence.
< 10% impotence rate 10-30% impotence (recovery period required).
Suitable for unifocal tumours Suitable for multifocal tumours.
<20% recurrence rate. PSA recurrence between 10 and 30% depending on extent of tumour.
Can be repeated. Cannot be repeated
Needs active ongoing surveillance  

Conclusion

  • Focal IRE treatment for the treatment of localised prostate cancer is safe.
  • IRE is 97% effective in the eradication of the index lesion of the prostate.
  • There is a < 15% recurrence rate in the rest of the prostate at five years of followup.
  • IRE has low toxicity and lower common side effects compared to established treatments.
  • IRE is suitable for recurrences after radiation therapy.
  • Major complications have not occurred in our series of 200 patients with up to five year followup.
  • MRI is useful in the followup of patients however it misses between 10 and 20% of recurrences which can only be picked up by transperineal biopsy.
  • IRE ideally is used selectively in focal intermediate grade prostate cancer to avoid over treatment by more conventional treatments
  • Multifocal intermediate and high grade prostate cancer generally are much more serious conditions than focal intermediate grade prostate cancer and until IRE can be shown to have equal cancer cure rates compared to surgery and radiotherapy in this higher risk group, more conventional methods such as surgery and radiation therapy should be used.

Publications

  • Blazevski, A., Scheltema, M. J., Amin, A., Thompson, J. E., & Lawrentschuk, N. (2019). Irreversible electroporation (IRE): A narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU International. Advance online publication. https://doi.org/10.1111/bju.14951
  • Blazevski, A., Scheltema, M. J., Amin, A., Thompson, J. E., & Lawrentschuk, N. (2020). Irreversible electroporation (IRE): A narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU International, 125(3), 369–378. https://doi.org/10.1111/bju.14951
  • Blazevski, A., Amin, A., Scheltema, M. J., Balakrishnan, A., Haynes, A. M., Barreto, D., Cusick, T., Thompson, J., & Stricker, P. D. (2021). Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World Journal of Urology, 39(4), 1107–1114. https://doi.org/10.1007/s00345-020-03275-z
  • Blazevski, A., Geboers, B., Scheltema, M. J., Gondoputro, W., Doan, P., Katelaris, A., Agrawal, S., Baretto, D., Matthews, J., Haynes, A. M., Delprado, W., Shnier, R., Van den Bos, W., Thompson, J. E., Lawrentschuk, N., & Stricker, P. D. (2022). Salvage irreversible electroporation for radio-recurrent prostate cancer – the prospective FIRE trial. BJU International. Advance online publication. https://doi.org/10.1111/bju.15947
  • Blazevski, A., Gondoputro, W., Scheltema, M. J., Amin, A., Geboers, B., Barreto, D., Haynes, A. M., Shnier, R., Delprado, W., Agrawal, S., Thompson, J. E., & Stricker, P. D. (2022). Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. BMC Urology, 22(1), 28. https://doi.org/10.1186/s12894-022-00978-w
  • Blazevski, A., Scheltema, M. J., Yuen, B., Masand, N., Nguyen, T. V., Delprado, W., Shnier, R., Haynes, A., Cusick, T., Thompson, J., & Stricker, P. (2020). Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: A biopsy-monitored prospective cohort. European Urology Oncology, 3(3), 382–390. https://doi.org/10.1016/j.euo.2019.04.008
  • Cussenot, O., & Stricker, P. D. (2021). Irreversible electroporation for patients with localised prostate cancer: Expert opinion on this versatile therapeutic approach. EMJ Urology, 9(1), 56–62. https://www.emjreviews.com/urology/article/irreversible-electroporation-for-patients-with-localised-prostate-cancer-expert-opinion-on-this-versatile-therapeutic-approach-j180121
  • Deivasigamani, S., Kotamarti, S., Rastinehad, A. R., Lebastchi, A. H., Tay, K. J., Polascik, T. J., Zargar, H., Mains, E., Sidana, A., Gorin, M. A., Siddiqui, M. M., Doshi, C., Halpern, J. A., Kinnaird, A., Johnson, B., Yaxley, W. J., Grummet, J., Kasivisvanathan, V., Oto, A., … Eggener, S. E. (2023). Primary whole-gland ablation for the treatment of clinically localized prostate cancer: A Focal Therapy Society Best Practice Statement. European Urology, 84(6), 547–560. https://doi.org/10.1016/j.eururo.2023.06.013
  • Durazo-Ruiz, F. O., Roldán-Testillano, R., Rodriguez-Sanchez, L., Laguna, M. P., Mendez-Bisgaard, L., Arezki, A., Elkhatib, H., Hevia-Feliu, A., Zhang, K., Fainberg, J., Perlis, N., Rosette, J. J. L., Miñana-López, B., de Reijke, T. M., Anidjar, M., Emberton, M., Stricker, P. D., & Sanchez-Salas, R. (2025). Irreversible electroporation in focal therapy for prostate cancer: Current status and future directions. Prostate International. Advance online publication. https://doi.org/10.1016/j.prnil.2025.11.001
  • Emberton, M., de Reijke, T., Stricker, P., Miñana, B., Bianco, F., Dominguez Escrig, J. L., Lantz, A., & Sanchez-Salas, R. (2023). Revisiting Delphi to create a basis for the future of focal therapy for prostate cancer. The Journal of Urology. Advance online publication. Urology Journal URL-D-23-00730.
  • Geboers, B., Scheltema, M. J., Blazevski, A., Katelaris, A., Doan, P., Ali, I., Agrawal, S., Barreto, D., Matthews, J., Haynes, A. M., Delprado, W., Shnier, R., Thompson, J. E., & Stricker, P. D. (2023). Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer. BJU International. Advance online publication. https://doi.org/10.1111/bju.15948
  • Geboers, B., Scheltema, M. J., Jung, J., Bakker, J., Timmer, F. E. F., Cerutti, X., Katelaris, A., Doan, P., Gondoputro, W., Blazevski, A., Agrawal, S., Matthews, J., Haynes, A. M., Robertson, T., Thompson, J. E., Meijerink, M. R., Clark, S. J., de Gruijl, T. D., & Stricker, P. D. (2024). Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation – IRE-IMMUNO study. BJU International. Advance online publication. https://doi.org/10.1111/bju.16496
  • Geboers, B., Gondoputro, W., Thompson, J. E., Reesink, D. J., van Riel, L. A. M. J. G., Zhang, D., Blazevski, A., Doan, P., Agrawal, S., Matthews, J., Haynes, A. M., Liu, Z., Delprado, W., Shnier, R., de Reijke, T. M., Lawrentschuk, N., Stijns, P. E. F., Yaxley, J. W., Scheltema, M. J., & Stricker, P. D. (2022). Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following irreversible electroporation—A multicenter validation study. European Urology Focus, 8(6), 1732–1739. https://doi.org/10.1016/j.euf.2022.04.010
  • Geboers, B., Meijer, D., Counter, W., Gianduzzo, T., Kwan, L., Yaxley, J., Roberts, M., Lawrencehuk, N., Katelaris, A., Doan, P., Agrawal, S., Scheltema, M. J., & Stricker, P. (2024). Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU International, 133(Suppl 4), 14–22. https://doi.org/10.1111/bju.16207
  • Lantz, A., Nordlund, P., Falagario, U., Jäderling, F., Özbek, O., Clements, M., Discacciati, A., Grönberg, H., Eklund, M., Stricker, P., Emberton, M., Aly, M., & Nordström, T. (2023). Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. European Urology Open Science, 51, 89–94. https://doi.org/10.1016/j.euros.2023.03.003
  • Ong, S., Chen, K., Grummet, J., Yaxley, J., Scheltema, M. J., Stricker, P., Tay, K. J., & Lawrentschuk, N. (2022). Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU International. Advance online publication. https://doi.org/10.1111/bju.15883
  • Rodríguez-Sánchez, L., Emberton, M., de Reijke, T., Stricker, P., Miñana, B., Bianco, F., Escrig, J. L. D., Lantz, A., & Sanchez-Salas, R. (2023). Revisiting Delphi to create a basis for the future of focal therapy for prostate cancer. The World Journal of Men’s Health. Advance online publication. https://doi.org/10.5534/wjmh.230160
  • Scheltema, M. J., & Stricker, P. D. (2025). Prospective multicentre validation of focal irreversible electroporation as an attractive treatment option for localised intermediate-risk prostate cancer. European Urology. Advance online publication. https://doi.org/10.1016/j.eururo.2025.10.003
  • Scheltema, M. J., Katelaris, A., & Stricker, P. D. (2023). Salvage irreversible electroporation for radio-recurrent prostate cancer. Nature Reviews Urology, 20(6), 359–371. https://doi.org/10.1038/s41585-023-00750-1
  • Scheltema, M. J., Chang, J. I., Bohm, M., van den Bos, W., Blazevski, A., Gielchinsky, I., Kalsbeek, A. M. F., van Leeuwen, P. J., Nguyen, T. V., de Reijke, T. M., Siriwardana, A. R., Thompson, J. E., de la Rosette, J. J., & Stricker, P. D. (2018). Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World Journal of Urology, 36(7), 1019–1025. https://doi.org/10.1007/s00345-018-2281-z
  • Scheltema, M. J., Chang, J. I., van den Bos, W., Gielchinsky, I., Nguyen, T. V., de Reijke, T. M., Siriwardana, A. R., Bohm, M., de la Rosette, J. J., & Stricker, P. D. (2018). Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagnostic and Interventional Radiology, 24(5), 268–275. https://doi.org/10.5152/dir.2018.17374
  • Scheltema, M. J., Geboers, B., Blazevski, A., Doan, P., Katelaris, A., Agrawal, S., Barreto, D., Shnier, R., Delprado, W., Thompson, J. E., & Stricker, P. D. (2022). Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU International. Advance online publication. https://doi.org/10.1111/bju.15946
  • Scheltema, M. J., van den Bos, W., Siriwardana, A. R., Kalsbeek, A. M. F., Thompson, J. E., Ting, F., Bohm, M., Haynes, A. M., Shnier, R., Delprado, W., & Stricker, P. D. (2017). Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU International, 120(S3), 51–58. https://doi.org/10.1111/bju.13991
  • Scheltema, M. J., O’Brien, T. J., van den Bos, W., de Bruin, D. M., Davalos, R. V., van den Geld, C. W. M., Laguna, M. P., Neal, R. E., Varkarakis, I. M., Skolarikos, A., Stricker, P. D., de Reijke, T. M., Arena, C. B., & de la Rosette, J. J. (2019). Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences. Therapeutic Advances in Urology, 11, Article 1756287219852305. https://doi.org/10.1177/1756287219852305
  • Storino Ramacciotti, L., Abreu, A. L., Crouzet, S., Macek, P., Miles, B. J., Horuz, R., Nunes-Carneiro, D., Stricker, P., Scionti, S., & Laguna, M. P. (2024). Salvage treatments after focal therapy for prostate cancer—a comprehensive review. Prostate Cancer and Prostatic Diseases. Advance online publication. https://doi.org/10.1038/s41391-024-00875-3
  • Ting, F., Tran, M., Böhm, M., Siriwardana, A., van Leeuwen, P. J., Haynes, A. M., Delprado, W., Shnier, R., & Stricker, P. D. (2015). Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer and Prostatic Diseases, 19(1), 46–52. https://doi.org/10.1038/pcan.2015.47
  • Ting, F., van Leeuwen, P. J., & Stricker, P. D. (2016). Step-by-step technique for irreversible electroporation of focal prostate cancer: An instructional video guide. Journal of Vascular and Interventional Radiology, 27(4), 568–572. https://doi.org/10.1016/j.jvir.2016.01.003
  • Valerio, M., Stricker, P. D., Ahmed, H. U., Dickinson, L., Ponsky, L., Shnier, R., Allen, C., & Emberton, M. (2014). Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 17(4), 343–347. https://doi.org/10.1038/pcan.2014.33
  • van den Bos, W., Scheltema, M. J., Siriwardana, A. R., Kalsbeek, A. M. F., Thompson, J. E., Ting, F., Bohm, M., Haynes, A. M., Shnier, R., Delprado, W., & Stricker, P. D. (2018). Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU International, 121(5), 716–724. https://doi.org/10.1111/bju.13983
  • van Riel, L. A. M. J. G., Geboers, B., Kabaktepe, E., Blazevski, A., Reesink, D. J., Stijns, P., Stricker, P. D., Casanova, J., Dominguez-Escrig, J. L., de Reijke, T. M., Scheltema, M. J., & Oddens, J. R. (2022). Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU International, 130(2), 224–232. https://doi.org/10.1111/bju.15759
  • Williams, I. S. C., Katelaris, A., Geboers, B., Doan, P., Delprado, W., Scheltema, M. J., & Stricker, P. (2024). Transrectal ultrasound as real-time confirmation of adequate needle positioning during irreversible electroporation in focal therapy of prostate cancer. Videourology, 37(4), 1–2. https://doi.org/10.1089/vid.2023.0046
  • Zhang, K., Stricker, P., Löhr, M., Stehling, M., Suberville, M., Cussenot, O., Lunelli, L., Ng, C. F., Teoh, J., Laguna, P., & de la Rosette, J. (2024). A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate Cancer and Prostatic Diseases. Advance online publication. https://doi.org/10.1038/s41391-023-00783-y

Presentations

  1. Stricker PD. Nanoknife focal therapy. Invited speaker. 3rd Friends of Israel Urological Symposium 5-7th July 2016. Tel-Aviv, Israel.
  2. Tran M, Jackson B, Boehm M, Haynes A-M, Stricker P, Irreversible Electroporation for Focal Prostate Cancer: Safety, Short-term Functional and Oncological Outcomes. Poster Presentation. 68th Urological Society of Australia and New Zealand Annual Scientific Meeting 11th – 19th April 2015, Adelaide, South Australia
  3. Van den Bos W, Stricker PD et al. Focal Therapy Using IRE in prostate cancer. Synergy Miami, November 2016. Miami Beach, Florida USA.
  4. Siriwardana A, van den Bos W, Kalsbeek A, Thompson J, Ting F, Boehm M, Haynes A, Shnier R, Delprado W and Stricker PD. Focal Irreversible Electroporation (IRE) as a primary and salvage treatment for localised prostate cancer. USANZ 2017 Annual Scientific Meeting 24-27th February 2017, Canberra, Australia
  5. Scheltema, MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF. Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, Stricker PD. Focal Irreversible Electroporation as primary and salvage treatment for prostate cancer. 5th Global Congress on Prostate Cancer. 28 – 30 June 2017, Lisbon Portugal
  6. Scheltema MJ, Chang JI, van den Bos, Bohm M, Delprado W, Gielchinsky I, de Reijke TM, de la Rosette J, Sirawardana AR, Shnier R, Stricker PD. Diagnostic Accuracy of Mulitparametric Resonance Imaging Following Prostate Cancer Focal Therapy with Irreversible Electroporation. 93rd Annual Meeting Western Section of the American Urological Association, 6 -10 August 2017, Vancouver British Columbia Canada
  7. Scheltema MJ, Chang JI, van den Bos, Gielchinsky I, de Reijke TM, Sirawardana AR, Bohm M, de la Rosette J, Stricker PD. Genito-Urinary Function and Quality of Life after Focal Irreversible Electroporation of Different Prostate Segments. 93rd Annual Meeting Western Section of the American Urological Association, 6 -10 August 2017, Vancouver British Columbia Canada
  8. Scheltema MJ, Chang JI, Bohm B, van den Bos W, Gielchinsky I, Kalsbeek AF, van Leeuwen PJ, de Reijke TM, Siriwardana AR, de la Rosette JJ. Stricker PD. Pair-matched Patient-reported Quality of Life following Focal Irreversible Electroporation versus Robot-assisted Radical Prostatectomy. 37th Congress of the Societe Internationale d’Urologie. 19-22 October 2017, Lisbon Portugal.
  9. Stricker PD Focal Nanoknife Therapy Invited speaker Tolmar National Symposium
  10. Blazevski, A (On behalf of P Stricker) - Ideal framework for the introduction of Nanoknife - 38th Congress of the Société Internationale d’Urologie, 2018, Seoul, Korea
  11. Blazevski A, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stricker P. Oncological Outcomes of Focal Irreversible Electroporation as Primary Treatment for Clinically Significant Localised Prostate Cancer. 38th Congress of the Société Internationale d’Urologie. 2018, Seoul, Korea
  12. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Is it time for prostate cancer’s lumpectomy? Focal irreversible electroporation (IRE) for localised clinically significant prostate cancer. 26th ASMR NSW ASM 2018
  13. Blazevski A, Pidsley R, Qu W, Norbie D, Luu L, Chang J, Yuen B, Scheltema MJ, Masand N, Haynes AM, Nguyen Q, Stirzaker C, Song J, Stricker P, Clark S. When Focal Therapy Fails for Localised Prostate Cancer – Can Epigenetics Predict Which Patients Fail and Improve Patient Selection? ANZUP ASM 8 – 10 July 2018. Sydney, Australia.
  14. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Focal irreversible electroporation as salvage treatment for localised radio-recurrent prostate cancer – Initial results and initiation of the FIRE trial. ANZUP ASM 8 – 10 July 2018. Sydney, Australia.
  15. Stricker P, Blazevski A, Scheltema MJ, Thompson J, Haynes AM, Nyguen Q, Chang, J, Yuen B. Oncological outcomes of irreversible electroporation (Nanoknife) for localised clinically significant prostate cancer at single Australia centre. 6th Edition Global Congress on Prostate Cancer (PROSCA 2018). 28 – 30 June 2018. Frankfurt, Germany
  16. Blazevski A, Yuen B, Scheltema MJ, Chang J, Masand N, Haynes AM, Nguyen Q, Stricker P. Is it time for prostate cancer’s lumpectomy? – Focal irreversible electroporation (IRE) for localised clinically significant prostate cancer. ASMR NSW Annual Scientific Meeting, June 2018. Sydney, Australia.
  17. Blazevski A, Yuen B, Scheltema MJ, Chang K, Masand N, Haynes AM, Nguyen Q, Stricker P. 5 years of Irreversible Electroporation (Nanoknife) for Localised Prostate Cancer. Asia-Pacific Prostate Conference 2018. Brisbane, Australia.
  18. Blazevski A, Stricker P. Where is the prostate cancer recurrence after radiation therapy? Implications for biopsy and focal salvage therapy. USANZ NSW Section Meeting. 1 – 3 November 2018. Cypress Lakes, Hunter Valley, NSW, Australia.
  19. Stricker, P - Key note speaker for salvage prostate cancer treatment - Hadassah Medical Center, Jerusalem, 2018
  20. Stricker, P - Introduction of NanoKnife to Amsterdam - National Cancer Institute – 2018
  21. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Focal Irreversible Electroporation for Radiorecurrent Prostate Cancer – Update on Current Results and Establishment of the FIRE trial. TROG Annual Scientific Meeting 2019. Melbourne, Australia
  22. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Update on 12-Month Biopsy Proven Oncological and Functional Outcomes of Primary Irreversible Electroporation for Localised Prostate Cancer. USANZ Annual Scientific Meeting 2019. Brisbane, Queensland
  23. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Salvage Irreversible Electroporation for Locally Recurrent Prostate Cancer after Radiotherapy – Oncological and Functional Outcomes. USANZ Annual Scientific Meeting 2019. Brisbane, Queensland
  24. Amin A, Blazevski A, Scheltema MJ, Thompson J, Stricker P. Salvage Radical Prostatectomy After Focal Irreversible Electroporation for Prostate Cancer: A Case Series Reporting Oncological Outcomes. Société International d’Urologie 2019 – Athens.
  25. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Shnier R, Stricker P. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. AUA 2019 – Annual Scientific Meeting – Chicago.
  26. Blazevski A, Cusick T, Haynes AM, Stricker P. Evolution of Irreversible Electroporation into a prostate cancer treatment – From the laboratory to Urologists. AUA 2019 – Annual Scientific Meeting – Chicago.
  27. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Salvage irreversible electroporation for locally recurrent prostate cancer after radiotherapy – Oncologic and functional outcomes. EAU 2019 – Annual Scientific Meeting – Barcelona.
  28. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Stricker P. Update on 12-month biopsy-proven oncological and functional outcomes of primary irreversible electroporation for localised prostate cancer. EAU 2019 – Annual Scientific Meeting – Barcelona.
  29. Blazevski A, Scheltema MJ, Yuen B, Masand N, Haynes AM, Cusick T, Shnier R, Stricker P. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. EAU 2019 – Annual Scientific Meeting – Barcelona
  30. Geboers B, Scheltema MJ, Jung J ... Stricker PD. Irreversible Electroporation of Intermediate risk prostate cancer mitigates immune suppression and induces systemic antitumor T cell activation Presented at USANZ Annual Scientific Meeting 2024

Contact

If you would like further information about NanoKnife® IRE focal therapy for prostate cancer, or to enquire about an appointment or second opinion with Professor Phillip Stricker, please use the contact form on his website.

Professor Stricker and his team at St Vincent's Clinic, Sydney, welcome enquiries from patients, referring physicians, and medical colleagues both within Australia and internationally.

Contact Professor Stricker